Health Care/Hospital
NEXTBIOMEDICAL, Fast Resorbable Microsphere 'Nexsphere-F' : Clinical Study Results on 155 Patients Published in the JVIR
* Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for treating joint pain, have been published in the est...
2025-03-17 21:00
2090
WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs
* Fourth-Quarter Revenue Reached RMB11,539 Million, Up 6.9% Year-over-Year * 2024 Revenue Reached RMB39,241 Million, Up 5.2% Year-over-Year (Excluding COVID-19 Commercial Project of 2023) * Full-Year Net Profit Attributable to the Owners of the Company Reached RMB9,450 Million[1], Diluted Ea...
2025-03-17 20:19
3011
Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies
HANGZHOU, China, March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced the successful completion of a new round of financing. Heda Health Fund an...
2025-03-17 18:00
2020
Fangzhou Inc.'s H2H Smart Healthcare Platform Honored as one of Guangdong's Premier High-Tech Innovation Products
GUANGZHOU, China, March 17, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, today announced that its proprietary "H2H Smart Healthcare Innovation Platform" has been distinguished as a "2024Guangdong Province Premier High-Qual...
2025-03-17 15:43
1819
Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer
HONG KONG, March 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasop...
2025-03-17 11:49
1983
Accropeutics Secured $12 Million in Series B Plus Financing
* Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). * Cash runway extended into the second half of 20...
2025-03-14 16:23
2375
MATELASER Introduces X1 Performance: The Ultimate Portable High-Energy Laser Therapy System for Pain Management
MIAMI, March 13, 2025 /PRNewswire/ -- MATELASER, INC., a pioneering force in laser therapy technology, is proud to announce the launch of the X1 Performance, the portable high-energy laser therapy system, designed to meet the highest U.S. medical quality standards for pain management, sports rec...
2025-03-13 22:00
2281
Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation
CAMBRIDGE, Mass., March 13, 2025 /PRNewswire/ -- Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a$110 million Series E financing led by a private equity fund of Value Partners ...
2025-03-13 21:00
3051
Amcor prices private offering of $2.2 billion of senior unsecured notes
ZURICH, March 13, 2025 /PRNewswire/ -- Amcor plc (NYSE:AMCR; ASX:AMC) ("Amcor") announced today that Amcor Flexibles North America, Inc. ("AFNA"), a wholly-owned subsidiary of Amcor, has priced a private offering (the "Offering") of guaranteed senior notes in an aggregate principal amount of$2.2 ...
2025-03-13 18:11
3872
WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025
SHANGHAI, March 13, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, has been honored with...
2025-03-13 13:54
2573
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
SHANGHAI, March 13, 2025 /PRNewswire/ -- BioCity Biopharmaceutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), to evaluate the combination of BioCity's BC3195 ...
2025-03-13 13:17
5749
Ping An Health Reports First Full-Year Profit in 2024
Synergies Between Health Care and Insurance Drive Scalable Growth AI Innovations Fuel Continued Success SHANGHAI and HONG KONG, March 12, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health" or "the Company", Stock Code: 1833.HK) announc...
2025-03-13 09:31
4566
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
* STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. * Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA to help...
2025-03-13 07:30
2239
111, Inc. to Participate in Fireside Chat with Water Tower Research on March 26, 2025
SHANGHAI, March 12, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will par...
2025-03-12 19:00
2142
Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results and a Cash Dividend
BEIJING, March 12, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and twelve months ended...
2025-03-12 18:18
3879
GenScript Biotech Corporation Reports FY 2024 Results
Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth. PISCATAWAY, N.J., March 12, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548.HK), a leading global technology and service provider of life science R&D and manufac...
2025-03-12 14:40
3727
Caliway's CBL-514 Phase 2 Study (CBL-0202) Accepted for Publication in the Aesthetic Surgery Journal
Advancing Scientific Recognition in Non-Surgical Fat Reduction * Caliway's CBL-514 Phase 2 study (CBL-0202) has been accepted for publication inAesthetic Surgery Journal (ASJ), the top-ranked journal in aesthetic medicine and plastic surgery. * Clinical data (ITT population) showed that over ...
2025-03-12 14:29
2047
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies
- Élancé Therapeutics aims to improve current obesity treatment, specifically to increase overall body weight loss and fat mass loss, but preserve and even increase muscle and lean mass - Élancé Therapeutics will leverage HCAb-based bispecific antibody technology to advance these next-generation ...
2025-03-12 12:41
2182
Flat Medical Announces Key U.S. Leadership Appointments
PITTSBURGH, PA., March 11, 2025 /PRNewswire/ -- Flat Medical announces strategic additions and promotions to its U.S. executive leadership team, positioning the company for continued growth in the North American medical technology sector. Mark Rabe has joined Flat Medical as Director of Sales an...
2025-03-11 22:30
2054
WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs
SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates...
2025-03-11 21:20
2021
Week's Top Stories
Most Reposted
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 279 media titles]
2026-01-01 10:00
Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 274 media titles]
2025-12-30 20:12
ACEN completes transition to 100% renewable energy
[Picked up by 274 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 264 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 261 media titles]
2025-12-29 14:27Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
7609
